hs27  (ATCC)

Journal: Cancer Diagnosis & Prognosis

Article Title: Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant Disease

doi: 10.21873/cdp.10405

Figure Lengend Snippet: Gemcitabine and rMETase sensitivity of HT1080 fibrosarcoma cells, gemcitabine-resistant HT1080 (GR-HT1080) cells, and Hs27 normal fibroblasts (mean±standard deviation). A) Sensitivity to gemcitabine in HT1080 cells. B) Sensitivity to rMETase in HT1080 cells. C) Sensitivity to gemcitabine in GR-HT1080 cells. D) Sensitivity to rMETase in GR-HT1080 cells. E) Sensitivity to gemcitabine in Hs27 cells. F) Sensitivity to rMETase in Hs27 cells.

Article Snippet: The HT1080 and Hs27 cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA).

Techniques: Standard Deviation

Journal: Cancer Diagnosis & Prognosis

Article Title: Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant Disease

doi: 10.21873/cdp.10405

Figure Lengend Snippet: Efficacy of the combination of gemcitabine and rMETase on HT1080 fibrosarcoma cells and Hs27 normal human fibroblasts. A) HT1080 cells. 1: control (DMEM); 2: gemcitabine [12.8 nM (IC 50 )]; 3: rMETase [0.75 U/ml (IC 50 )]; 4: gemcitabine [12.8 nM (IC 50 )] and rMETase [0.75 U/ml (IC 50 )]. B] Hs27 normal human fibroblasts. 1: control (DMEM); 2: gemcitabine [4.48 nM (IC 50 )]; 3: rMETase [0.93 U/ml (IC 50 )]; 4: gemcitabine [4.48 nM (IC 50 )] and rMETase [0.93 U/ml (IC 50 )].

Article Snippet: The HT1080 and Hs27 cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA).

Techniques: Control

Journal: Drug Design, Development and Therapy

Article Title: Identification of Coumarin-Chalcone and Coumarin-Pyrazoline Derivatives as Novel Anti- Toxoplasma gondii Agents

doi: 10.2147/DDDT.S495089

Figure Lengend Snippet: Cytotoxicity Profile of Chalcone Derivatives (5a-i) and N-Acetyl Pyrazolines Derivatives (6a-i) Against Mouse L929 and Human Hs27 Fibroblasts

Article Snippet: The Hs27 human fibroblasts (Hs27, CRL-1634, ATCC, Manassas, VA, USA), used as host cells for T. gondii , were maintained in high glucose DMEM (ATCC, Manassas, VA, USA), supplemented with 10% fetal bovine serum (ATCC, Manassas, VA, USA), 100 I.U./mL penicillin and 100 mg/mL streptomycin (Merck KGaA, Darmstadt, Germany).

Techniques:

Journal: Drug Design, Development and Therapy

Article Title: Identification of Coumarin-Chalcone and Coumarin-Pyrazoline Derivatives as Novel Anti- Toxoplasma gondii Agents

doi: 10.2147/DDDT.S495089

Figure Lengend Snippet: The cytotoxic effects of chalcone-bearing coumarins 5a-i and N -acetyl pyrazoline-bearing coumarins 6a-i against mouse L929 (blue) and human Hs27 (red) fibroblasts. The CC 30 values represent the concentration of the samples to cause cytotoxic effects in 30% of the cells. CC 30 and SEM values were based on the non-linear regression analysis. Reference drugs: Pyr: pyrimethamine; Tri: trimethoprim; Sulf: sulfadiazine.

Article Snippet: The Hs27 human fibroblasts (Hs27, CRL-1634, ATCC, Manassas, VA, USA), used as host cells for T. gondii , were maintained in high glucose DMEM (ATCC, Manassas, VA, USA), supplemented with 10% fetal bovine serum (ATCC, Manassas, VA, USA), 100 I.U./mL penicillin and 100 mg/mL streptomycin (Merck KGaA, Darmstadt, Germany).

Techniques: Concentration Assay

Journal: Drug Design, Development and Therapy

Article Title: Identification of Coumarin-Chalcone and Coumarin-Pyrazoline Derivatives as Novel Anti- Toxoplasma gondii Agents

doi: 10.2147/DDDT.S495089

Figure Lengend Snippet: Profile of Anti-T. Gondii Activity of the Target Chalcone-Bearing Coumarins 5a-I and N-Acetyl Pyrazoline-Bearing Coumarins 6a-I

Article Snippet: The Hs27 human fibroblasts (Hs27, CRL-1634, ATCC, Manassas, VA, USA), used as host cells for T. gondii , were maintained in high glucose DMEM (ATCC, Manassas, VA, USA), supplemented with 10% fetal bovine serum (ATCC, Manassas, VA, USA), 100 I.U./mL penicillin and 100 mg/mL streptomycin (Merck KGaA, Darmstadt, Germany).

Techniques: Activity Assay

Journal: Drug Design, Development and Therapy

Article Title: Identification of Coumarin-Chalcone and Coumarin-Pyrazoline Derivatives as Novel Anti- Toxoplasma gondii Agents

doi: 10.2147/DDDT.S495089

Figure Lengend Snippet: Anti- T. gondii activity of the coumarin-6-sulfonamide bearing chalcone derivatives (5a-i) and N -acetyl pyrazolines (6a-i). IC 50 values with SEM are shown on the left y-axis, representing the concentration of the sample to cause inhibition of T. gondii growth by 50%. Values were based on the non-linear regression analysis. The right, y-axis (red dots above bars) represents the selectivity index SI, a measure of efficacy calculated by CC 30 Hs27/IC 50 Tg. Reference drugs: Pyr: pyrimethamine; Tri: trimethoprim; Sulf: sulfadiazine.

Article Snippet: The Hs27 human fibroblasts (Hs27, CRL-1634, ATCC, Manassas, VA, USA), used as host cells for T. gondii , were maintained in high glucose DMEM (ATCC, Manassas, VA, USA), supplemented with 10% fetal bovine serum (ATCC, Manassas, VA, USA), 100 I.U./mL penicillin and 100 mg/mL streptomycin (Merck KGaA, Darmstadt, Germany).

Techniques: Activity Assay, Concentration Assay, Inhibition